- Home
- ZYXI vs ENTX Comparison
ZYXI vs ENTX Comparison
Compare ZYXI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYXI
- ENTX
- Stock Information
- Founded
- ZYXI 1996
- ENTX 2010
- Country
- ZYXI United States
- ENTX Israel
- Employees
- ZYXI N/A
- ENTX N/A
- Industry
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZYXI Health Care
- ENTX Health Care
- Exchange
- ZYXI Nasdaq
- ENTX Nasdaq
- Market Cap
- ZYXI 66.5M
- ENTX 69.6M
- IPO Year
- ZYXI N/A
- ENTX 2018
- Fundamental
- Price
- ZYXI $2.18
- ENTX $1.79
- Analyst Decision
- ZYXI Buy
- ENTX Strong Buy
- Analyst Count
- ZYXI 3
- ENTX 1
- Target Price
- ZYXI $10.25
- ENTX $10.00
- AVG Volume (30 Days)
- ZYXI 262.3K
- ENTX 30.9K
- Earning Date
- ZYXI 04-29-2025
- ENTX 05-09-2025
- Dividend Yield
- ZYXI N/A
- ENTX N/A
- EPS Growth
- ZYXI N/A
- ENTX N/A
- EPS
- ZYXI 0.09
- ENTX N/A
- Revenue
- ZYXI $192,354,000.00
- ENTX $181,000.00
- Revenue This Year
- ZYXI N/A
- ENTX N/A
- Revenue Next Year
- ZYXI $23.16
- ENTX N/A
- P/E Ratio
- ZYXI $24.22
- ENTX N/A
- Revenue Growth
- ZYXI 4.36
- ENTX N/A
- 52 Week Low
- ZYXI $1.93
- ENTX $1.41
- 52 Week High
- ZYXI $12.19
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- ZYXI 26.14
- ENTX 49.59
- Support Level
- ZYXI $2.03
- ENTX $1.50
- Resistance Level
- ZYXI $2.24
- ENTX $1.84
- Average True Range (ATR)
- ZYXI 0.18
- ENTX 0.11
- MACD
- ZYXI 0.17
- ENTX 0.03
- Stochastic Oscillator
- ZYXI 38.46
- ENTX 85.50
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.